scholarly journals Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas

2017 ◽  
Vol Volume 10 ◽  
pp. 1155-1164 ◽  
Author(s):  
Federica Recine ◽  
Alberto Bongiovanni ◽  
Nada Riva ◽  
Valentina Fausti ◽  
Alessandro De Vita ◽  
...  
2005 ◽  
Vol 3 (2) ◽  
pp. 198-205
Author(s):  
Margaret von Mehren

Medical management of soft tissue sarcomas (STS) has been restricted by the limited availability of active drugs. A plethora of new oncologic agents are now available, many of which have specific therapeutic targets. Gemcitabine and docetaxel is a combination of drugs that have limited single-agent activity. Yondelis, a novel chemotherapeutic that binds DNA and functions partially by inhibiting transcription, is being tested alone and in combination with doxorubicin. Inhibitors of mTOR, a serine/threonine kinase that regulates cell cycle activation and cell growth, are also being tested. Growth factor receptor inhibitors are being evaluated in a variety of sarcomas that have been found to express the targets. In addition, a variety of agents are being assessed in gastrointestinal stromal tumors (GIST). Single agents and agents combined with imatinib are being tested in imatinib-refractory and in metastatic GIST. The increased use of targeted agents underscores the need for understanding sarcoma biology.


2009 ◽  
Vol 37 (1) ◽  
pp. 42-48 ◽  
Author(s):  
Merdan Fayda ◽  
Gorkem Aksu ◽  
Fulya Yaman Agaoglu ◽  
Ahmet Karadeniz ◽  
Emin Darendeliler ◽  
...  

1986 ◽  
Vol 18 (S2) ◽  
pp. S23-S24 ◽  
Author(s):  
J. de Kraker ◽  
P. A. Voûte

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 10586-10586
Author(s):  
Kwai Han Yoo ◽  
Seung Tae Kim ◽  
Jeeyun Lee ◽  
Se Hoon Park ◽  
Sung Joo Kim ◽  
...  

2010 ◽  
Vol 10 (2) ◽  
pp. 249-260 ◽  
Author(s):  
Dimitrios Krikelis ◽  
Ian Judson

Sign in / Sign up

Export Citation Format

Share Document